Product Description
Privigen is an intravenous Ig therapy that contains antibodies—essential proteins in your immune system that identify and destroy bacteria and viruses that cause disease. The primary antibody found in Privigen, immunoglobulin G, is the main type of antibody made by your immune system. (Sourced from: https://www.privigen.com/what-is-privigen/cidp)
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Orphan Drug - Scleroderma, General *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|